1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Enforcement in Brief

A consent decree brings Downing Labs to heel, while Pfizer JV partner Zhejiang Hisun gets a warning letter and a shortage-related reprieve on import alert. Meanwhile, Ipca is hit with a warning letter, Chan Yat Hing’s cosmetics ploy is blocked, and two Chinese firms get import alerts.

With a little help from the Department of Justice, FDA has finally been able to stop Dallas-compounder Downing Labs, previously known as NuVision, from manufacturing adulterated drugs.

At FDA’s request, a US District Court judge on Jan. 8 entered into a consent decree for permanent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

PDUFA VIII: FDA Pilot Programs, Workforce Challenges Could Shape Renewal Debate

 
• By Sue Sutter

The next iteration of the user fee program could depart from longstanding agency commitments to issue formal guidance given the Trump Administration’s deregulatory philosophy, policy experts said.

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

US FDA Begins ‘Competitive Search’ For New Drugs Center Director

 
• By Derrick Gingery and Sarah Karlin-Smith

The FDA deputy commissioner emailed staff asking anyone interested in the position to send her their curriculum vitae, an unusual method for finding candidates for a high-level position.

Pink Sheet Podcast: Examining George Tidmarsh’s Departure As Head Of US FDA’s Drug Center

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors explain Tidmarsh’s abrupt resignation as the FDA’s chief drug regulator and the potential impact on the already reeling agency.

More from North America

FDA Office of New Drugs Director Mary Thanh Hai Not Interested In CDER Director Job

 
• By Sue Sutter

The 27-year agency veteran has not been formally approached about filling the vacancy created by George Tidmarsh’s resignation, but also is not interested in the position, the Pink Sheet has learned.

Novo, Lilly Lower GLP-1 Prices, ‘Enabling’ Medicare, Medicaid Coverage In Obesity

 
• By Cathy Kelly

The $245 price agreed to by both firms may be in line with the maximum fair price that Medicare negotiated for Novo Nordisk’s semaglutide products.

Oz: CMS Developing Plans To Incentivize Domestic Manufacturing

 
• By Sarah Karlin-Smith

The Trump Administration’s efforts to encourage more US-based pharmaceutical manufacturing have largely centered on FDA plans and Trump’s threats of tariffs and Most Favored Nation pricing, but Oz hinted Medicare and Medicaid soon may soon announce new incentives.